Intellia
Intellia
Focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
Gene Editing
CRISPR Technology
Cell Engineering
Bioinformatics
Drug Development
Open roles at Intellia
0 open roles
No open positions at this time
Closed positions
4 positions
Our Culture
Remote
Closed 5 months ago
ONE Intellia
Remote
Closed 5 months ago
Join Us
Remote
Closed 5 months ago
Careers
Remote
Closed 5 months ago
Products and services
CR
CRISPR/Cas9 Gene Editing Platform
Gene Editing Technology
NT
NTLA-2001
Gene Editing Therapy
NT
NTLA-3001
Gene Editing Therapy
EX
Ex Vivo Cell Engineering
Cell Engineering Service
NT
NTLA-2002
Gene Editing Therapy
NE
Neurological Disease Programs
Gene Editing Therapy
PR
Primary Hyperoxaluria Program
Gene Editing Therapy
MO
Modular CRISPR Platform
Platform Technology
AS
ASGR1 Program
Gene Editing Therapy
IN
In Vivo Gene Editing Services
Gene Editing Service
LI
Lipid Nanoparticle Delivery System
Drug Delivery Technology
NTLA-5001
Cell Therapy
IM
Immunology Pipeline
Therapeutic Pipeline
NTLA-2003
Gene Editing Therapy
Asgard Platform
Platform Technology
LI
Lipid Nanoparticle Platform
Technology Platform
ON
Oncology Cell Therapies
Cell Therapy
Engineered Cell Medicines
Cell Therapy
CR
CRISPR Platform Technology
Technology Platform
Similar companies
Moderna
American biotechnology company
Cambridge, Massachusetts
1,001-5,000 employees
Public
Valuation $47B
Insulet
Multinational healthcare company.
Bedford, Massachusetts, United States
501-1,000 employees
Public
Valuation $2.1B
Pfizer
American multinational pharmaceutical and biotechnology corporation
New York City, New York
10,001+ employees
Public
Valuation $280B
888 open jobs
Merck
Global medicines, vaccines, and animal health company
Rahway, New Jersey
10,001+ employees
Public
Valuation $208B
1,462 open jobs
CRISPR Therapeutics
Swiss-American biotechnology company
Cambridge, Massachusetts, United States
201-500 employees
Public
Valuation $2.9B
16 open jobs
Latest updates
All
X
News
HN
YouTube
Intellia Files BLA After Lonvo-z Meets Phase 3 Endpoints - CRISPR Medicine News
CRISPR Medicine News
News
·
2 months ago
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
·
2 months ago
·
1
Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA) - TipRanks.com
Bull signal if I ever saw one
·
2 months ago
·
89
·
34
Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing - simplywall.st
simplywall.st
News
·
2 months ago
Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture
·
2 months ago
·
28
Show 15 more
Total Views
0
Total Apply Clicks
0
Total Mock Apply
0
Total Bookmarks
0
Reviews
2.7
2 reviews
Work-life balance
3.0
Compensation
3.0
Culture
2.0
Career
2.5
Management
1.5
25%
Recommend to a friend
Pros
Potential for meaningful medical impact
Working on innovative treatments
Opportunity to help patients with rare diseases
Cons
Poor management decisions
Unfair layoff practices
Favoritism in promotions
Salary Ranges
47 data points
Mid/L4
Mid/L4
1 reports
$214,500
total per year
Base
$165,000
Stock
-
$214,500
$214,500
Interview experience
1 interviews
Difficulty
3.0
/ 5
Duration
2-5w
Interview process
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Offer
Contact and location